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Abstract
Background: Hospitalized patients are at increased risk for candidemia and invasive candidiasis (C/IC). Improved
therapeutic regimens with enhanced clinical and pharmacoeconomic outcomes utilizing existing antifungal agents
are still needed.
Methods: An open-label, non-comparative study evaluated an intravenous (IV) to oral step-down strategy. Patients
with C/IC were treated with IV anidulafungin and after 5 days of IV therapy had the option to step-down to oral
azole therapy (fluconazole or voriconazole) if they met prespecified criteria. The primary endpoint was the global
response rate (clinical + microbiological) at end of treatment (EOT) in the modified intent-to-treat (MITT) population
(at least one dose of anidulafungin plus positive Candida within 96 hours of study entry). Secondary endpoints
included efficacy at other time points and in predefined patient subpopulations. Patients who stepped down early
(≤ 7 days’ anidulafungin) were identified as the “early switch” subpopulation.
Results: In total, 282 patients were enrolled, of whom 250 were included in the MITT population. The MITT global
response rate at EOT was 83.7% (95% confidence interval, 78.7–88.8). Global response rates at all time points were
generally similar in the early switch subpopulation compared with the MITT population. Global response rates were
also similar across multiple Candida species, including C. albicans, C. glabrata, and C. parapsilosis. The most common
treatment-related adverse events were nausea and vomiting (four patients each).
Conclusions: A short course of IV anidulafungin, followed by early step-down to oral azole therapy, is an effective
and well-tolerated approach for the treatment of C/IC.
Trial registration: ClinicalTrials.gov: NCT00496197
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Background
Candidemia and invasive candidiasis (C/IC) are import-
ant causes of morbidity and complications in patient
populations including neutropenic patients, solid-organ
and stem-cell transplant recipients, patients with indwell-
ing intravascular devices, and patients in intensive care.
The incidence of candidemia appears to be considerably
higher in the United States (US) compared with Canada
and Europe, with the exception of Denmark [1,2]. The
attributable mortality of candidemia in US studies has
ranged from 19% to 49% [3,4]. Over the past decade,
the incidence of candidal infections due to non-albicans
Candida (NAC) species that are resistant to fluconazole
has increased, highlighting the need for optimized antifun-
gal regimens.
* Correspondence: swansr1@pfizer.com
9Pfizer Inc, New York, NY, USA
Full list of author information is available at the end of the article
© 2014 Vazquez et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Vazquez et al. BMC Infectious Diseases 2014, 14:97
http://www.biomedcentral.com/1471-2334/14/97
An initial short course of an intravenous (IV) echino-
candin, followed by the option to step-down to oral azole
therapy, could be as effective for the treatment of C/IC as
conventional 10- to 14-day IV regimens, including for the
rarer Candida species. Additionally, this step-down strat-
egy could have added benefits, such as better tolerability,
reduced use of IV catheters, earlier patient discharge, and
significant cost savings, as documented in oral step-down
antibiotic regimens [5-11], although prospective data for
de-escalation in antifungal therapy are lacking.
In vitro, the echinocandins (including anidulafungin)
have reported potent fungicidal activity against most
Candida species and demonstrated a favorable safety
profile [12-18]. Echinocandins are recommended as the
treatment of choice for severely ill and neutropenic patients
with proven or suspected invasive candidiasis in recent
clinical practice guidelines [13]. An azole, such as flucona-
zole, is widely used and recommended as a first-line agent
for the treatment of C/IC in non-critically ill patients
[13]. Voriconazole is also recommended as a step-down
therapy for patients with infection due to some of the
NAC species following first-line treatment with an echino-
candin or amphotericin B.
In patients with candidemia, continual therapy until
14 days after the first negative blood culture is recom-
mended. The Infectious Diseases Society of America
(IDSA) guidelines include the recommendation to step-
down to oral azole therapy as early as possible once the
patient is clinically stable and blood cultures have become
negative [13]. However, this specific strategy is based on
limited clinical evidence for antifungal treatment and has
not been prospectively studied. The European Society for
Clinical Microbiology and Infectious Diseases (ESCMID)
suggests simplification of treatment by stepping down to
oral fluconazole after 10 days of treatment if the patient
is stable, and tolerates oral therapy, and if the Candida
species is susceptible [19]. However neither of these
specific strategies have been prospectively studied and the
appropriate timing of step-down therapy remains unclear.
Recognizing this gap in current knowledge, we evaluated
the efficacy and safety of utilizing initial therapy with IV
anidulafungin, followed by an optional early step-down to
oral fluconazole or voriconazole for the treatment of C/IC
in adults. The study was specifically designed to evaluate
anidulafungin treatment in a broad group of patients with
C/IC caused by various species of Candida and to explore
use of an early step-down strategy in a real-world setting.
Methods
Study design
This was a Phase IV, open-label, noncomparative study,
involving 44 centers across the US and four centers in
the Republic of Korea. The four Korean centers were
added to increase enrollment and because treatment
practices for invasive candidiasis were similar to those in
the US. The trial was conducted in accordance with the
ethical principles decreed by the Declaration of Helsinki
and in compliance with International Conference on
Harmonization Good Clinical Practice Guidelines. The
final protocol, any amendments, and the informed consent
document were reviewed and approved by the Institutional
Review Boards and/or Independent Ethics Committees at
each of the investigational centers (Additional file 1:
Table S1). All patients or their proxy provided written
informed consent prior to study initiation.
Patients ≥ 18 years of age were enrolled in the study if
the presence of candidemia (positive blood culture) or
invasive candidiasis (positive culture from a normally
sterile site) was demonstrated from a culture obtained
within 96 hours of study entry. In addition, the presence
of one or more of the following signs and symptoms
of infection was also required: fever or hypothermia;
hypotension; localized signs and symptoms of inflam-
mation; or radiological findings of invasive candidiasis.
Patients were allowed to participate if they had received
no more than 48 hours of systemic azole therapy. Prior
prophylaxis with azoles was permitted provided it was
discontinued prior to the study. Patients were excluded
if they had one of the following: life expectancy of less
than 1 month; hypersensitivity to echinocandins or azoles;
prior treatment with either an echinocandin or ampho-
tericin B; systemic antifungal therapy had failed for the
current episode of C/IC; a diagnosis of fungal endophthal-
mitis with involvement of the vitreous humor; chronic re-
fractory neutropenia and were not expected to recover
(defined as absolute neutrophil count < 500 cells/mm3 for
28 days prior to the baseline visit); or the presence of con-
firmed or suspected Candida osteomyelitis, endocarditis,
or meningitis. Removal of IV catheters suspected to be
the cause of infection was required within 24 hours of
starting study drug. To allow for delays in scheduling
catheter removal in these seriously ill patients, patients
who had all catheters removed or replaced to another
anatomical location by study Day 3 were considered to
have had their catheters removed.
Study treatment
All patients received 200 mg IV anidulafungin as a single
loading dose and 100 mg IV anidulafungin daily there-
after for a maximum of 28 days. After 5 days’ IV anidula-
fungin, investigators could transition patients to an oral
azole if they met the following criteria: ability to tolerate
oral therapy; afebrile for > 24 hours; hemodynamically
stable; not neutropenic; and had documented clearance
of Candida from the bloodstream. Patients were not
randomized or pre-selected to receive early oral step
down therapy; rather the decision was made based on the
patient’s condition and protocol guidelines. Per protocol,
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patients with positive baseline cultures for C. albicans and
C. parapsilosis were stepped down to oral fluconazole
(400 mg/day); all other patients were stepped down to oral
voriconazole (200 mg twice daily). Combined IV and oral




The following efficacy analysis sets were considered:
Intent-to-treat (ITT) population, all subjects who had
taken at least one dose of study drug. All safety analyses
were based on the ITT population.
Modified intent-to-treat (MITT) population, all ITT
subjects with a positive baseline culture for a Candida
species. Missing and unknown global responses were not
included in the analysis. Patients in the MITT population
were further categorized into those who stepped down to
oral azole therapy and those who remained on IV therapy.
Early switch subpopulation, patients who stepped down
to oral azole therapy by Day 7 of the study (Days 1 and 2
of potential switch to oral therapy). Missing and unknown
global responses were not included in the analysis.
An additional sensitivity analysis was performed, which
set missing values and unknown responses as failures. This
allowed a more direct comparison between studies, as the
global response rates assessed in previous anidulafungin
studies set missing and unknown values to failure [17].
Efficacy
Blood cultures were performed at the screening visit and
repeated daily until Day 5, and at the end of treatment
(EOT) visit. If a positive culture was obtained on Day 5,
a repeat culture was required on Day 7. Patients with
candidemia whose blood culture remained positive on
Day 7 were considered treatment failures and were dis-
continued from the study. Susceptibility testing was
conducted on all baseline isolates using the Clinical
Laboratory Standards Institute M27 microbroth dilu-
tion method and M27-A3 breakpoints.
The primary efficacy endpoint was the global response
rate (clinical + microbiological response) at EOT based
on the MITT population. A successful global response
was defined as both clinical success (cure – resolution of
signs and symptoms of Candida infection, or improve-
ment – significant, but incomplete, resolution of signs
and symptoms of Candida infection) and microbiological
success (eradication – negative follow-up culture for
Candida species, or presumed eradication – follow-up
culture was not available and clinical response was
defined as cure or improvement). Global responses were
also assessed independently by a data adjudication
committee (DAC), which periodically reviewed certain
specified endpoints as defined separately in a charter,
but the assessments by the investigator were considered
the primary endpoint.
In the primary MITT analysis, global response rates
at EOT and end of study (EOS) were calculated with
missing/unknown outcomes excluded. However, sensi-
tivity analyses were also performed, in which missing/
unknown outcomes were set to failure.
Key secondary endpoints and other parameters of the
study included: global response rate at secondary time
points, such as the end of IV (EOIV) treatment, at 2 weeks
post-treatment, and at EOS (6 weeks post-therapy); time
to negative blood culture; global response rate for the
subset of subjects with NAC infections; and all-cause
and attributable mortality.
Safety
Clinical and laboratory evaluations were also performed
periodically throughout the study. Routine safety assess-
ments were made during IV and oral treatment as well
as during the follow-up period. All adverse events (AEs)
and serious adverse events (SAEs) were monitored.
Post-hoc analyses
Baseline characteristics, global response rates at EOT, and
secondary time points for the early switch subpopulation
were assessed alongside all MITT patients.
Statistical analyses
The planned sample size was 286 patients, which, assum-
ing an evaluability rate of 70% and a 50:50 distribution of
albicans to NAC infections, would result in approximately
100 patients with baseline infections caused by non-albi-
cans species. There were no formal pre-specified statistical
decision rules, as this was a single-arm estimation study.
No formal hypotheses were tested in this study and the
design did not allow for statistical comparisons to be made




In total, 294 patients were screened for entry into the
study (270 in US, 24 in Korea), and 282 patients were
enrolled and received treatment. The study was conducted
between July 2007 and June 2010. Patient disposition is
shown in Figure 1. In the MITT population, 54% were
male, with a mean (standard deviation [SD]) age of 55.4
(16.9) years, and mean (SD) Acute Physiology and Chronic
Health Evaluation (APACHE)-II score of 14.3 (6.7).
C. albicans (45%) was the most common baseline patho-
gen isolated. For the early switch subpopulation (step-
down within 7 days of starting treatment with anidulafun-
gin), demographics and characteristics were generally
similar to the MITT population.
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The APACHE-II score was lower in the early switch
subpopulation (mean [SD] 12.7 [6.2]) compared with the
MITT population. Patient demographics and baseline
characteristics for both the MITT population and the
early switch subpopulation are summarized in Table 1.
Of the 250 MITT patients, 100 (40%) remained on
anidulafungin treatment throughout the study and had a
median duration of 12.0 days of therapy (range, 1–29).
One hundred and fifty (60%) of the MITT patients stepped
down to oral azole therapy, with a median duration of
6.0 days of parenteral therapy (Table 2). There were 102 pa-
tients in the early switch subpopulation; the median
duration of IV therapy prior to oral step-down was
5.0 days (range, 1–6) and the median duration of overall
antifungal therapy was 14.0 days (range, 5–56). There
were 48 patients in the late switch subpopulation; the
median duration of IV therapy prior to oral step-down
was 10.0 days (range, 6–27) and the median duration
of overall antifungal therapy was 19.0 days (range,
8–42). The durations of therapy for the MITT popula-
tion, and the early switch subpopulation, late switch
subpopulation, and no switch subpopulation are shown
in Table 2.
Efficacy
The global response rates at EOT were as follows: 83.7%
(95% confidence interval [CI], 78.7–88.8; 170/203 patients)
in the MITT; 89.9% (95% CI, 86.0–93.8) as assessed by the
DAC; and 68.0% (95% CI, 62.2–73.8; 170/250 patients) for
the sensitivity analysis. The global response rates for the
primary analysis and sensitivity analyses at EOIV, 2 weeks
post-treatment, and EOS are shown in Table 3.
In the early switch subpopulation (≤ 7 days’ anidula-
fungin), the global response rate at EOT was 90.0% (95%
CI, 83.8–96.2) and 79.4% (95% CI, 71.6–87.3) for the
sensitivity analysis. In general, patients in the early switch
subpopulation had global response rates that were higher
than the MITT population at all time points (Table 3).
The highest successful global response rates at EOT
were observed in patients with C. albicans (87.0% [95% CI,
80.1–93.8]) and C. glabrata (86.5% [95% CI, 77.3–95.8])
infections, while the lowest response rates were observed
in patients with C. krusei (60.0% [95% CI, 29.6–90.4])
isolated at baseline. Global response rates for the MITT
and early switch subpopulations at EOT and secondary
time points per baseline pathogen are shown in Table 4.
In the early switch subpopulation there were no failures in
patients with C. tropicalis or C. krusei infection through-
out the study time points, although the numbers were
small (9 and 3 patients at EOT for C. tropicalis or
C. krusei, respectively).
Median time to negative blood culture for all patients
was two days (with Day 1 being the first dose of study
drug), and approximately 90% of patients achieved a nega-
tive blood culture by Day 5. All but six baseline isolates
were susceptible to anidulafungin and only one of the pa-
tients with a resistant baseline pathogen was a treatment
failure. Three patients receiving oral fluconazole and four
patients receiving oral voriconazole had baseline isolates
which were resistant to fluconazole and voriconazole,
respectively. There were no treatment failures among
these seven patients. Baseline isolates from all other pa-
tients were documented susceptible to the oral agents used.
Safety
In total, 33 (11.7%) patients reported a total of 59
treatment-related AEs. Nausea and vomiting were the
most frequently reported treatment-related AEs, both
reported in four patients (1.4%). Of the 13 patients who
permanently discontinued from the study, only one dis-
continuation was anidulafungin-related (an episode of
vomiting). Three patients experienced SAEs related to
treatment with anidulafungin as judged by the site principal
investigator – acute renal failure, abnormal liver func-
tion test, and systemic Candida. One patient receiving
Completed study n = 160
*Two patients received both oral fluconazole and oral voriconazole.
Abbreviations used: IV, intravenous; MITT, modified intent-to-treat.
Analyzed:
Full analysis set n = 282
    - Excluded n = 32
         - No positive baseline culture n = 32
MITT population n = 250
    - Switched to oral azole therapy n = 150
         - Voriconazole n = 52*
         - Fluconazole n = 99*
         - Early switch subpopulation n = 102
    - Remained on IV anidulafungin n = 100
Assessed for eligibility
(n = 294)
Received treatment with IV anidulafungin n = 282
Discontinuations n = 122
    - Patient died n = 43
    - Related to study drug n = 4
    - Unrelated to study drug n = 75
Excluded n = 12
    - Did not receive at least
      one dose of study
      medication n = 12
Figure 1 CONSORT diagram.
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voriconazole was identified with a treatment-related
SAE case of C. difficile colitis, and one patient was identi-
fied with acute renal failure, hypotension, and dehydration
as a treatment-related SAE with fluconazole.
There were 65 deaths (23.0%) recorded in the 282 sub-
jects receiving at least one dose of anidulafungin. Forty-
three of these deaths occurred during the study period
(Figure 1). Twenty subjects died after withdrawing from
the study for a variety of reasons and two subjects died
after completing the study. None of the deaths were con-
sidered to be related to study drug or treatment regimens.
There were 14 deaths (13.7%) recorded in the 102 subjects
in the early switch population.
Discussion
The early step-down from an echinocandin to an oral
azole among stable patients with IC is a suggested strategy
in the recently published treatment guidelines for C/IC
[13]. However, this recommendation is based on limited
clinical evidence, expert opinion, and common practice.
Indeed, in recent trials of the treatment of candidemia,
step-down to an azole was prohibited before 10 days of
parenteral therapy with an echinocandin [14,17,20].
In this study, a step-down strategy from IV to oral
therapy was incorporated as part of the study design.
Sixty percent (60%) of patients enrolled in this study
underwent early step-down (by Day 7) to either flucona-
zole or voriconazole. Although baseline characteristics
for the early switch subpopulation were generally similar
to the overall MITT population, some interesting differ-
ences were noted. In the early switch subpopulation
compared with the overall MITT population, C. glabrata
isolates were less common. Importantly, fewer early
switch patients had an APACHE-II score >20 and fewer
had a length of intensive care unit stay ≥4 days. This
suggests that patients in the early switch subpopulation
were less severely ill. In general, the early switch
Table 1 Combined summary of demography and baseline







Number of patients 250 102
Female (%) 115 (46.0) 49 (48.0)
Mean age (SD) 55.4 (16.9) 53.9 (17.7)
Median age (range) 56.0 (19–89) 53.0 (19–88)
Race (%)
White 164 (65.6) 69 (67.6)
Black 52 (20.8) 28 (27.5)
Asian 26 (10.4) 1 (1.0)
Other 8 (3.2) 4 (3.9)
Baseline characteristics
Number of patients (%) 250 (100.0) 102 (100.0)
Baseline site of infection (%)
Blood only 210 (84.0) 86 (84.3)
Other sterile site 38 (15.2) 16 (15.7)
Blood and other sterile site 2 (0.8) 0
APACHE-II score
n (%) 249 (99.6) 102 (100.0)
Mean (SD) 14.3 (6.7) 12.7 (6.2)
Median (range) 14.0 (2–36) 12.0 (2–29)
> 20 (%) 47 (18.8) 14 (13.7)
ANC
n (%) 227 (90.8) 93 (91.2)
≤ 500 cells/mm3 (%) 9 (3.6) 2 (2.0)
Length of ICU stay ≥ 4 days (%)* 82 (34.3) 23 (23.5)
Invasive candidiasis related to IV catheter*
Yes (%) 104 (45.8) 44 (46.3)
All catheters removed within 3 days of therapy?
Yes 98 (94.2) 41 (93.2)
No 6 (5.8) 3 (6.8)
No (%) 41 (18.1) 14 (14.7)
All catheters removed within 3 days of therapy?
Yes 25 (61.0) 8 (57.1)
No 16 (39.0) 6 (42.9)
Baseline isolates of Candida species, n (%)
C. albicans 112 (44.8) 46 (45.1)
C. glabrata 64 (25.6) 20 (19.6)
C. parapsilosis 41 (16.4) 20 (19.6)
C. tropicalis 27 (10.8) 11 (10.8)
C. krusei 11 (4.4) 4 (3.9)
Other 9 (3.6) 6 (5.9)
Table 1 Combined summary of demography and baseline
characteristics of the MITT population and early switch
subpopulation (Continued)
Most commonly reported comorbidities
(terms reported from ≥ 10%), n (%)
Anemia 127 (50.8) 58 (56.9)
Nausea 70 (28.0) 29 (28.4)
Diabetes mellitus 48 (19.2) 27 (26.5)
Hypokalemia 51 (20.4) 26 (25.5)
Malnutrition 49 (19.6) 24 (23.5)
*Risk factors for invasive candidiasis and catheter management data were
systematically collected only after Case Report Form (CRF) revision shortly after
study start. Percentages are based on the actual number of patients enrolled
in the study after these CRFs were incorporated.
Abbreviations used: ANC, absolute neutrophil count; APACHE, Acute Physiology
and Chronic Health Evaluation; ICU, intensive care unit; IV, intravenous; MITT,
modified intent-to-treat; SD, standard deviation.
Vazquez et al. BMC Infectious Diseases 2014, 14:97 Page 5 of 10
http://www.biomedcentral.com/1471-2334/14/97
Table 2 Duration of therapy (MITT, early switch subpopulation, late switch subpopulation, and no switch subpopulation)
MITT population Early switch subpopulation Late switch subpopulation No switch subpopulation
(n = 250) (n = 102) (n = 48) (n = 100)
n (%) Median, days Range, days n (%) Median, days Range, days n (%) Median, days Range, days n (%) Median, days Range, days
Duration of overall therapy
(IV + oral)
250 (100) 14.0 1-56 102 (100) 14.0 5-56 48 (100) 19.0 8-42 100 (100) 12.0 1-29
Duration of IV anidulafungin
portion of therapy*
250 (100) 6.0 1-29 102 (100) 5.0* 1-6* 48 (100) 10.0 6-27 100 (100) 12.0 1-29
Study day of step-down to
oral therapy
150 (60) 6.0 1-28 102 (100) 6.0 1-7 48 (100) 11.0 8-28 - - -
1-5 7 (4.7) - - 7 (6.9) - - - - - - - -
6 77 (51.3) - - 77 (75.5) - - - - - - - -
7 18 (12.0) - - 18 (17.6) - - - - - - - -
8-14 38 (25.3) - - - - - 38 (79.2) - - - - -
15-21 6 (4.0) - - - - - 6 (12.5) - - - - -
22-28 4 (2.7) - - - - - 4 (8.3) - - - - -
*Represents the duration of IV therapy prior to oral step-down. Four patients from the early switch subpopulation had to be stepped back to IV therapy after initially stepping down to oral azole as they later became
unable to tolerate oral medication. Total duration of IV therapy for these patients is, therefore, longer than reported here.



















subpopulation showed response rates similar to the
MITT population and these response rates were main-
tained through the end of study. These results demon-
strate the efficacy of including an early step-down
strategy in treating patients with C/IC.
Direct comparison across trials should be regarded
cautiously; however, global response rates in both the
MITT population and the early step-down subpopula-
tion from this study were comparable to other trials that
evaluated anidulafungin for the treatment of C/IC [14-17].
This included the study by Reboli and colleagues, which
demonstrated higher response rates for anidulafungin
compared to fluconazole for the treatment of C/IC [17].
The most relevant parameter in comparing efficacy results
with those in the Reboli et al. study was the global
response in the sensitivity analysis (missing/unknown
set to failure). In the current study, the global response
rates in the sensitivity analysis at EOT for the MITT
and early step-down subpopulation were 68% and 79.4%,
respectively. This compared with a global response rate at
EOIV of 75.6% from the Reboli et al. study. Furthermore,
the survival rates and safety profile in the current study
were comparable to the Reboli et al. study and other
previously reported clinical trials [14-17]. This comparison
suggests that a C/IC treatment regimen utilizing anidu-
lafungin in a strategy of early step-down yields similar
efficacy and outcome results when compared to previous
studies that required a minimum 10 days of parenteral
anidulafungin therapy.
The early step-down approach used in the current
study was effective against a wide range of Candida
species. Successful response rates were comparable to
the rates seen in C. albicans infections in patients with
either C. glabrata or C. parapsilosis infections, the sec-
ond and third most common pathogens isolated in this
patient population. Additionally, failures were not reported
for C. tropicalis or C. krusei infections in the early switch
subpopulation. Successful global response rates across
all time points were similar for voriconazole and flu-
conazole (data not shown), indicating that either drug
could be employed as a step-down therapy after IV
anidulafungin.
Table 3 Responses at EOT and secondary timepoints in the MITT population and early switch subpopulation
MITT population Early switch subpopulation
(n = 250) (n = 102)
Response n/N (%) [95% CI]a n/N (%) [95% CI]a
Global response at EOT
Success 170/203 (83.7) [78.7–88.8] 81/ 90 (90.0) [83.8–96.2]
Sensitivity analysis* 170/250 (68.0) [62.2–73.8] 81/102 (79.4) [71.6–87.3]
Failure 33 9
Missing/unknown 47 12
Clinical response at EOT
Success 174/187 (93.0) [89.4–96.7] 83/ 89 (93.3) [88.0–98.5]
Sensitivity analysis* 174/250 (69.6) [63.9–75.3] 83/102 (81.4) [73.8–88.9]
Failure 13 6
Missing/unknown 63 13
Microbiological response at EOT
Success 183/192 (95.3) [92.3–98.3] 87/ 90 (96.7) [93.0–100.0]
Sensitivity analysis* 183/250 (73.2) [67.7–78.7] 87/102 (85.3) [78.4–92.2]
Failure 9 3
Missing/unknown 58 12
Global response at secondary time points n/N (%) [95% CI] n/N (%) [95% CI]
EOIV 208/235 (88.5) [84.4–92.6] 97/101 (96.0) [92.2–99.8]
Sensitivity analysis* 208/250 (83.2) [78.6–87.8] 97/102 (95.1) [90.9–99.3]
Week 2 follow-up 148/194 (76.3) [70.3–82.3] 72/ 86 (83.7) [75.9–91.5]
Sensitivity analysis* 148/250 (59.2) [53.1–65.3] 72/102 (70.6) [61.7–79.4]
EOS 131/187 (70.1) [63.5–76.6] 68/ 86 (79.1) [70.5–87.7]
Sensitivity analysis* 131/250 (52.4) [46.2–58.6] 68/102 (66.7) [57.5–75.8]
*Missing/unknown values set as failures; a95% CI based on normal approximation to the binomial.
Abbreviations used: CI, confidence interval; EOIV, end of intravenous treatment; EOS, end of study; EOT, end of treatment; MITT, modified intent-to-treat.
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One hundred patients with candidemia remained on
IV anidulafungin throughout the study. These patients
tended to be more severely ill at baseline, as reflected in
a higher APACHE-II score, or were more likely to have
had recent abdominal surgery and the concern about ad-
equacy of oral absorption.
The high global response rate (88.5%) at EOIV is likely
to be reflective of the high level of activity of initial treat-
ment with anidulafungin; this is further supported by
the rapid eradication of Candida from blood cultures.
In contrast to prior candidemia studies, daily blood cul-
tures were required (Days 1–5), allowing for a rigorous
assessment of culture eradication times. The median
time to blood culture eradication in this study was two
days, consistent with the in vitro fungicidal activity of
anidulafungin and other echinocandins against most
Candida species [21].
Based on the findings of this study, patients with C/IC
are suitable candidates for step-down oral antifungal
therapy provided the Candida has been cleared from the
bloodstream, the patient is clinically stable and capable
of taking oral therapy. The advantages of the approach,
beyond its convenience and flexibility, include possible
additional clinical benefits, such as shorter duration or
need for intravascular catheters, decreased length of stay
and a potential cost saving, as documented for other,
antibiotic, step-down regimens [5-11].
Limitations of the study include the fact that the study
was not appropriately designed for statistical comparison
between the early switch subpopulation and the MITT.
Likewise, there was no controlling for baseline severity
factors between these two populations. Additionally, this
was an open-label study, therefore there was no active
or placebo comparator for the response rates observed.
Table 4 Global response rates by baseline pathogen in the MITT population and early switch subpopulation
MITT population Early switch subpopulation
Baseline pathogen EOT EOS EOT EOS
n (%) n (%) n (%) n (%)
[95% CI]* [95% CI]* [95% CI]* [95% CI]*
C. albicans
Subjects in analysis 92 84 41 40
Success 80 (87.0) 63 (75.0) 36 (87.8) 33 (82.5)
[80.1–93.8] [65.7–84.3] [77.8–97.8] [70.7–94.3]
Failure 12 (13.0) 21 (25.0) 5 (12.2) 7 (17.5)
C. glabrata
Subjects in analysis 52 48 18 17
Success 45 (86.5) 31 (64.6) 16 (88.9) 10 (58.8)
[77.3–95.8] [51.1–78.1] [74.4–100.0] [35.4–82.2]
Failure 7 (13.5) 17 (35.4) 2 (11.1) 7 (41.2)
C. parapsilosis
Subjects in analysis 34 32 18 18
Success 26 (76.5) 22 (68.8) 16 (88.9) 15 (83.3)
[62.2–90.7] [52.7–84.8] [74.4–100.0] [66.1–100.0]
Failure 8 (23.5) 10 (31.3) 2 (11.1) 3 (16.7)
C. tropicalis
Subjects in analysis 19 17 9 8
Success 15 (78.9) 12 (70.6) 9 (100.0) 8 (100.0)
[60.6–97.3] [48.9–92.2] [100.0–100.0] [100.0–100.0]
Failure 4 (21.1) 5 (29.4) 0 0
C. krusei
Subjects in analysis 10 10 3 3
Success 6 (60.0) 5 (50.0) 3 (100.0) 3 (100.0)
[29.6–90.4] [19.0–81.0] [100.0–100.0] [100.0–100.0]
Failure 4 (40.0) 5 (50.0) 0 0
*95% CI based on normal approximation to the binomial.
Abbreviations used: CI, confidence interval; EOS, end of study; EOT, end of treatment; MITT, modified intent-to-treat.
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Conclusions
A strategy utilizing initial therapy with anidulafungin
for 5 days followed by an optional step-down to oral
fluconazole or voriconazole, based on isolated Candida
species, is an effective and well-tolerated regimen and
could be employed as an alternative treatment regimen
for patients with C/IC. Shorter transition times may be
possible dependent upon earlier laboratory results and
patient response rates to initial anidulafungin parenteral
therapy. An IV to oral step-down strategy may have a
favorable impact on removal of intravascular devices,
hospital length of stay, and cost.
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